Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Randy Noelle
Dartmouth College, Department: Microbiology/immun/virology
Should you be removed from our database? Contact us at [email protected]. Read more below.
ImmuNext Inc.
Payment for services (e.g., consulting fees, honoraria, paid authorship)
ImmuNext is developing novel therapeutics that modulate the immune system to treat cancer and autoimmune diseases. This research project studies a molecule which ImmuNext has licensed.
Given Dr. Noelle's role as PI in this project, his financial interest in ImmuNext (equity and consulting income as described above) could significantly and directly affect the design, conduct, and reporting of the research.
Targeting VISTA eradicates large, established PD-1/CTLA-4 resistant tumors
Narrative. Targeting of immune negative checkpoint regulator (NCR) pathways is revolutionizing the treatment of human cancers and has established that these pathways are proven clinical targets in human disease. VISTA (V-region Immunoglobulin-containing Suppressor of T cell Activation), is a recently- identified, NCR ligand/receptor that is being developed as a target for human malignancies. Clinical trials with aVISTA antibodies have commenced. This proposal will define how VISTA controls the immune system to make protective immune responses to cancer and may help us to understand who will benefit the most from anti-VISTA therapy. Understanding how targeting this molecule cures cancer will provide guidance for future therapeutic applications in oncology.
Filed on August 30, 2017.
Tell us what you know about Randy Noelle's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Randy Noelle”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Randy Noelle | Dartmouth College | Conflict of Interest | ImmuNext Inc. | $550,000 - $599,999 |
| Randy Noelle | Dartmouth College | Conflict of Interest | ImmuNext Inc. | >$600,000 |
| Randy Noelle | Dartmouth College | Conflict of Interest | ImmuNext Inc | >$600,000 |
| Randy Noelle | Dartmouth College | Conflict of Interest | ImmuNext Inc | >$600,000 |
| Randy Noelle | Dartmouth College | Conflict of Interest | ImmuNext Inc. | >$600,000 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.